N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=760 Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
SARS-CoV-2 · COVID-19
Primary: SARS-CoV-2-specific Antibody Binding Response Rate (BAMA IgG1) by Region and Enrollment Group Among America Cohort — 15; 3; 16; 18 Participants
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
Phase 1 N=99 Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
Phase 3 N=30 Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2)
SARS-CoV 2 · ARDS
Primary: Change in Arterial Blood Oxygen Content to Fraction of Inspired Oxygen Ratio (PaO2/FiO2) — 10.7; 21.4; 61.1; 11.8 mmHg
N/A N=877 Q-POC SARS-CoV-2 Assay COVID-19 Clinical Evaluation
COVID-19
Primary: Number of Participants With Positive Results on Both the Q-POC SARS-CoV-2 Assay and the RT-PCR Comparator Test — 130 Participants
Phase 3 N=239 Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 26; 26…
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
Phase 1 N=91 Phase I Study to Assess the Safety and Immunology of a COVID-19 Vaccine With GRAd-COV2 Vaccine
COVID-19
Primary: Occurrence of Solicited Local AE Signs and Symptoms 7 Days Following the Vaccination — 10; 12; 10; 2 Participants
N/A N=91 Pandemic Triage Score in Patients With Known or Suspected Severe Acute Respiratory Syndrome (SARS) CoronaVirus (CoV) 2 Infection
SARS-CoV-2 Acute Respiratory Disease · Covid19
Primary: Number of Participants With Normal and Above Triage (STC-19) Score — 52; 12; 4; 5 Participants
Phase 4 N=217 Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
COVID-19
Primary: Number of Participants With Treatment Emergent Amino Acid Substitutions Greater Than (>) 5 Percent (%) and >50% Allelic Frequency in the Sotrovimab Epitope at Day 7…
N/A N=45 A Study of the GRIP Influenza and SARS-CoV-2 POC Assays
COVID-19 · Influenza
Primary: Positive Percent Agreement — 52 percent of nasal swabs
Phase 2 N=30 Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Covid19
Primary: Part A: Number of Participants With All Adverse Events (AEs) and Serious Adverse Events (SAEs) Through Day 29 — 0; 3; 0; 0 Participants
Phase 1 N=12 Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
COVID · Sars-CoV2 · COVID-19
Primary: Number of Major Hemorrhagic Complications Within 14 Days of Initiation of Treatment — 0 Participants
Phase 3 N=420 Sarilumab COVID-19
Corona Virus Infection
Primary: Time to Improvement in Clinical Status of Participants (Using 7-point Ordinal Scale Score) by at Least 2 Points — 10.0; 10.0; 12.0 days — p=0.9561
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
N/A N=300 Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
SARS-CoV 2 · COVID-19
Primary: Number of Participants With COVID-19 Antibodies — 8; 284 Participants — p=>0.18
N/A N=36 SARS-CoV-2 Human Challenge Characterisation Study
Covid19 · SARS-CoV Infection · Corona Virus Infection
Primary: Number of Unsolicited Adverse Events in Healthy Participants Challenged With Wild Type SARS-CoV-2 — 45 Unsolicited Adverse Events
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
Phase 2 N=47 PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
COVID-19
Primary: Mean Cycle Threshold (Ct) Values Through Day 3 as a Measure of Change in Viral Titers of SARS-CoV-2 — 24.36; 26.03; 28.42; 25.71 cycles
Phase 3 N=1,923 A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
SARS-CoV-2 Infection
Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years
N/A N=10 Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing
SARS-CoV2 Infection
Primary: Dental Health Care Worker (DHCW) Willingness to Participate in the Study — 10 Participants
Phase 1 N=23 RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers
Covid19
Primary: Grade 2 and Higher Adverse Events 4 Weeks After Administration. — 0; 0; 0; 0 Participants
Phase 2 N=1,758 A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
SARS-CoV-2 · Influenza
Primary: Parts 1 and 2: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 32; 36; 37; 43 Participants
N/A N=332 COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV2 Infection · COVID-19
Primary: Positive Percent Agreement — 53; 2 Participants
Phase 3 N=30,415 A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
SARS-CoV-2
Primary: Part A: Number of Participants With a First Occurrence of COVID-19 Starting 14 Days After Second Dose — 744; 55 Participants — p=<.0001
N/A N=99 COVID-19 MP Biomedicals Rapid SARS-CoV-2 Antigen Test Usability
Sars-CoV-2 Infection · COVID-19
Primary: 30 Candidate Ag Test Self-collections — 53; 0 Participants
N/A N=6,049 Characterising Transmission of SARS-CoV-2 in a Peri-urban Population in Mozambique
COVID-19
Primary: COVID-19 Disease Incidence Rate (Symptomatic Infections Per Month) — 364.5 infections per 1000 person-years
N/A N=143 HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists
COVID
Primary: Number of Participants With SARS-CoV-2 IgG Antibodies — 14 Participants